Cas no 66917-44-0 (Betamethasone 9,11-Epoxide 17,21-Dipropionate)
Betamethasone 9,11-Epoxide 17,21-Dipropionate Chemical and Physical Properties
Names and Identifiers
-
- Betamethasone 9,11-Epoxide 17,21-Dipropionate
- BETAMETHASONE 9,11-EPOXIDE 17,21-DIPROPIONATE,WHITE SOLID
- A)-9,11-Epoxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione
- A,11
- A,16
- Beclomethasone 9,11-Epoxide 17,21-Dipropionate
- 66917-44-0
- Betamethasone 9beta,11beta-epoxide 17,21-dipropionate
- 9.BETA.,11.BETA.-EPOXYBETAMETHASONE DIPROPIONATE
- SCHEMBL10908765
- Pregna-1,4-diene-3,20-dione, 9,11-epoxy-16-methyl-17,21-bis(1-oxopropoxy)-, (9beta,11beta,16beta)-
- B79EV94J1X
- BWSCDDHHJUGBSQ-XHYJHYNESA-N
- UNII-B79EV94J1X
- 9,11beta-Epoxy-16beta-methyl-3,20-dioxo-9beta-pregna-1,4-diene-17,21-diyl dipropanoate
- 9,11.BETA.-EPOXY-16.BETA.-METHYL-3,20-DIOXO-9.BETA.-PREGNA-1,4-DIENE-17,21-DIYL DIPROPANOATE
- 9beta,11beta-Epoxybetamethasone dipropionate
- [2-oxo-2-[(1S,2S,10S,11S,13S,14R,15S,17S)-2,13,15-trimethyl-5-oxo-14-propanoyloxy-18-oxapentacyclo[8.8.0.01,17.02,7.011,15]octadeca-3,6-dien-14-yl]ethyl] propanoate
- Beclomethasone dipropionate impurity J
- BECLOMETHASONE DIPROPIONATE IMPURITY J [EP IMPURITY]
- Q27274457
- (9beta,11beta,16beta)-16-Methyl-3,20-dioxo-9,11-epoxypregna-1,4-diene-17,21-diyl dipropanoate
- DTXSID10628431
- 9beta,11beta-epoxy-16beta-methyl-pregna-1,4-diene-17,21-diol-3,20-dione 17,21-dipropionate
- BETAMETHASONE 9.BETA.,11.BETA.-EPOXIDE 17,21-DIPROPIONATE
- PREGNA-1,4-DIENE-3,20-DIONE, 9,11-EPOXY-16-METHYL-17,21-BIS(1-OXOPROPOXY)-, (9.BETA.,11.BETA.,16.BETA.)-
- Betamethasone dipropionate impurity F
- 1-(4-Hydroxyphenyl)ethanone Oxime; Paracetamol Imp. G (EP); 4-Hydroxyacetophenone Oxime
-
- Inchi： 1S/C28H36O7/c1-6-23(31)33-15-21(30)27(35-24(32)7-2)16(3)12-20-19-9-8-17-13-18(29)10-11-25(17,4)28(19)22(34-28)14-26(20,27)5/h10-11,13,16,19-20,22H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,22-,25-,26-,27-,28+/m0/s1
- InChI Key： BWSCDDHHJUGBSQ-XHYJHYNESA-N
- SMILES： O1[C@H]2C[C@]3(C)[C@@](C(COC(CC)=O)=O)([C@@H](C)C[C@H]3[C@@H]3CCC4=CC(C=C[C@]4(C)[C@@]132)=O)OC(CC)=O
Computed Properties
- Exact Mass: 484.24600
- Monoisotopic Mass: 484.24610348g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 35
- Rotatable Bond Count: 8
- Complexity: 1060
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.5
- Topological Polar Surface Area: 99.3?2
Experimental Properties
- Density: 1.2±0.1 g/cm3
- Melting Point: 143-145°C
- Boiling Point: 597.7±50.0 °C at 760 mmHg
- Flash Point: 253.5±30.2 °C
- Solubility: Chloroform, Ethyl Acetate (Slightly), Methanol (Slightly)
- PSA: 99.27000
- LogP: 3.88590
- Vapor Pressure: 0.0±1.7 mmHg at 25°C
Betamethasone 9,11-Epoxide 17,21-Dipropionate Security Information
- Hazard Statement： CAUTION: May irritate eyes, skin
- Safety Instruction： CAUT
- Storage Condition：Refrigerator
Betamethasone 9,11-Epoxide 17,21-Dipropionate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | B327060-10mg |
Betamethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 10mg |
$ 170.00 | 2023-04-18 | ||
| TRC | B327060-20mg |
Betamethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 20mg |
$ 238.00 | 2023-04-18 | ||
| TRC | B327060-50mg |
Betamethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 50mg |
$ 459.00 | 2023-04-18 | ||
| TRC | B327060-100mg |
Betamethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 100mg |
$ 871.00 | 2023-04-18 | ||
| TRC | B327060-250mg |
Betamethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 250mg |
$ 1793.00 | 2023-04-18 | ||
| A2B Chem LLC | AH17390-10mg |
BetaMethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 98% (HPLC) | 10mg |
$212.00 | 2024-04-19 | |
| A2B Chem LLC | AH17390-25mg |
BetaMethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 98% (HPLC) | 25mg |
$256.00 | 2024-04-19 | |
| A2B Chem LLC | AH17390-100mg |
BetaMethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 98% (HPLC) | 100mg |
$634.00 | 2024-04-19 | |
| A2B Chem LLC | AH17390-250mg |
BetaMethasone 9,11-Epoxide 17,21-Dipropionate |
66917-44-0 | 98% (HPLC) | 250mg |
$1189.00 | 2024-04-19 |
Betamethasone 9,11-Epoxide 17,21-Dipropionate Suppliers
Audited Supplier
Betamethasone 9,11-Epoxide 17,21-Dipropionate Related Literature
-
Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
-
Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
-
Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
-
Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
Additional information on Betamethasone 9,11-Epoxide 17,21-Dipropionate
Betamethasone 9,11-Epoxide 17,21-Dipropionate: A Comprehensive Overview
Betamethasone 9,11-Epoxide 17,21-Dipropionate, also known by its CAS number 66917-44-0, is a synthetic corticosteroid with significant anti-inflammatory and immunosuppressive properties. This compound has been extensively studied for its therapeutic potential in various medical conditions, particularly in the treatment of inflammatory and immune-mediated diseases. The molecule's structure, characterized by the epoxide group at positions 9 and 11 and the dipropionate ester groups at positions 17 and 21, plays a crucial role in its pharmacokinetic and pharmacodynamic properties.
Recent advancements in corticosteroid research have shed light on the mechanisms underlying the efficacy of Betamethasone 9,11-Epoxide 17,21-Dipropionate. Studies have demonstrated that this compound exhibits potent anti-inflammatory activity by inhibiting the synthesis of pro-inflammatory cytokines and reducing the migration of leukocytes to inflamed tissues. Moreover, its immunosuppressive effects are mediated through the modulation of T-cell activation and cytokine production, making it a valuable agent in the management of autoimmune disorders.
The CAS number 66917-44-0 is often referenced in scientific literature to identify this compound accurately. Researchers have explored its application in treating conditions such as allergic rhinitis, eczema, and rheumatoid arthritis. Clinical trials have shown that Betamethasone 9,11-Epoxide 17,21-Dipropionate can effectively reduce symptoms associated with these diseases while minimizing systemic side effects due to its localized delivery mechanisms.
In terms of pharmacokinetics, Betamethasone 9,11-Epoxide 17,21-Dipropionate demonstrates a favorable absorption profile when administered topically or via intra-articular injection. Its metabolism involves hydrolysis of the dipropionate ester groups, which enhances its bioavailability and reduces systemic toxicity. This characteristic makes it an ideal candidate for prolonged use in chronic inflammatory conditions.
Recent studies have also investigated the potential of Betamethasone 9,11-Epoxide 17,21-Dipropionate in combination therapies. For instance, its synergistic effects with biologic agents such as tumor necrosis factor-alpha inhibitors have shown promising results in treating refractory cases of psoriasis and ankylosing spondylitis. These findings underscore the importance of further research into optimizing dosing regimens and exploring novel delivery systems for this compound.
The development of new formulations for Betamethasone 9,11-Epoxide 17,21-Dipropionate has been a focal point in recent years. Researchers are investigating nanoparticle-based delivery systems to enhance its targeting efficiency and reduce adverse effects. Such innovations could revolutionize the treatment of inflammatory diseases by providing safer and more effective therapeutic options.
In conclusion, Betamethasone 9,Epoxide Dipropionate, identified by CAS number 66944-0, remains a cornerstone in corticosteroid therapy due to its potent anti-inflammatory and immunosuppressive properties. Ongoing research continues to uncover new applications and improve delivery methods for this compound. As our understanding of its mechanisms deepens, so too does its potential to transform the treatment landscape for a wide range of inflammatory and immune-mediated disorders.
66917-44-0 (Betamethasone 9,11-Epoxide 17,21-Dipropionate) Related Products
- 72064-79-0(Prednisolone 21-Acetate 17-Valerate)
- 86401-95-8(6a-Methyl Prednisolone Aceponate)
- 15180-00-4(Prednival)
- 103228-03-1(Pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11-(3,3-dimethyl-1-oxobutoxy)-17-hydroxy-,monosodium salt, (11a)- (9CI))
- 912-38-9(9b,11b-Epoxy-17,21-dihydroxy-16b-methylpregna-1,4-diene-3,20-dione 21-Acetate)
- 205105-83-5(16b-Betamethasone 9,11-Epoxide 21-Propionate)
- 79578-39-5(Betamethasone 9,11-Epoxide 17-Propionate)
- 38680-83-0(9b,11b-Epoxy-17,21-dihydroxypregna-1,4-diene-3,20-dione 21-acetate)
- 77074-42-1(6a-Methyl Prednisolone 17-Hemisuccinate)
- 94237-35-1(9beta,11beta-Epoxy-17,21-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-di(acetate))
